Literature DB >> 9067581

Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias.

G Csanaky1, E Matutes, J A Vass, R Morilla, D Catovsky.   

Abstract

The expression of a series of adhesion receptors: L-selectins (CD62L): Leu-8, several integrins (LFA-1: CD11a/CD18, VLA-4: CD49d/CD29 and VLA-5: CD49e/CD29), ICAM-1(CD54) and the 'homing receptor' (CD44) were investigated by a dual color flow cytometry in 56 cases of B cell disorders namely, 39 chronic lymphocytic leukemias (CLL), four hairy cell leukemia (HCL), seven splenic lymphoma with villous lymphocytes (SLVL) and six other non-Hodgkin's lymphoma (NHL). The functional activity of L-selectins was assessed with L-selectin ligand analogs (polyphosphomonester core polysaccharide: PPME and fucoidin). Leukemic B cells were identified with phycoerythrin-conjugated monoclonal antibodies (McAbs) anti-CD19, anti-kappa/lambda investigated simultaneously for the expression of adhesion receptors estimated with fluorescein-isothiocyanate (FITC) conjugated McAbs. The percentage of leukemic cells expressing L-selectins (Leu-8) was high in CLL (52% of positive cases) and integrin expression (LFA-1, VLA-4, 5) was low (19 and 33%, respectively), while a reverse pattern, low Leu-8 (17%), and a high VLA-4 (77%), was observed in non-CLL cases. The expression of LFA-1 alpha-chain was variable in non-CLL cases, and the LFA-1 heterodimer was expressed on most clonal B cell in NHLs (92%). LFA-1 alpha-chain was detected on cells from only one HCL case, while beta2 integrin was regularly expressed on hairy cells. VLA-5 integrin was found on a relatively small number (26%) of mature B cell leukemias. A remarkable finding was the detection of ICAM-1 in all CLL cases albeit the number of positive cells was significantly lower (P < 0.05) compared to non-CLL cases. CD44 was expressed on a high number of neoplastic cells in all the investigated categories. There was no correlation between the expression of the adhesion molecules and clinical and laboratory parameters except for CD18 which was expressed on a significantly (P < 0.05) higher number of leukemic cells in CLL with more advanced stages. This study demonstrates that even closely related B cell leukemia/lymphomas have a certain well defined and strictly variable adhesion profile which is characteristic of the disease entity and therefore, the adhesion profile may offer additional information useful for differential diagnosis and study of disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067581     DOI: 10.1038/sj.leu.2400582

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

Review 1.  Hairy cell leukemia.

Authors:  Ronan Swords; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.

Authors:  Kristina M DiFranco; Rajesh H Kaswala; Chandni Patel; Chinnaswam Kasinathan; Scott C Kachlany
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

3.  The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival.

Authors:  Vanessa Stache; Lydia Verlaat; Marcel Gätjen; Kristina Heinig; Jörg Westermann; Armin Rehm; Uta E Höpken
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

Review 4.  The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.

Authors:  Jan A Burger; Mariela Sivina; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2011-03-25

5.  Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma.

Authors:  Jordi Bruna; Sergio Martínez-Yelamos; Esther Alonso; Vicente Romagosa; Jordi Arruga; Jordi Arruga; Alicia Domingo; Iñigo Rojas-Marcos; Josep Petit; Francisco Rubio
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

6.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

7.  Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.

Authors:  Rodrigo Jacamo; Ye Chen; Zhiqiang Wang; Wencai Ma; Min Zhang; Erika L Spaeth; Ying Wang; Venkata L Battula; Po Yee Mak; Katharina Schallmoser; Peter Ruvolo; Wendy D Schober; Elizabeth J Shpall; Martin H Nguyen; Dirk Strunk; Carlos E Bueso-Ramos; Sergej Konoplev; R Eric Davis; Marina Konopleva; Michael Andreeff
Journal:  Blood       Date:  2014-03-05       Impact factor: 22.113

Review 8.  New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia.

Authors:  C M Wendtner; B Schmitt; M Bergmann; T Röhnisch; R Buhmann; M Hallek
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.